Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee

Osteoarthritis, Knee Clinical Trial

Official title:

An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04119687
• Other study ID #: FX201-2019-001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 2, 2020
• Est. completion date: November 28, 2026

Study information

• Verified date: January 2024
• Source: Pacira Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This two-part study will be conducted in male and female patients, 30 - 80 years of age with painful OA of the index knee with Kellgren-Lawrence (K-L) Grade 2, 3 or 4.

Part 1 - Single Ascending Dose (SAD) Phase: Up to three ascending doses of FX201 will be tested in cohorts of 5-8 patients. Each patient will only receive one injection of FX201. An independent Data Monitoring Committee (DMC) will review safety and guide the conduct of the study.

Part 2 - Expansion Phase: Up to an additional 35 patients will be enrolled at each dose level reviewed by the DMC. Each patient will only receive one injection of FX201.

Description:

This two-part study will be conducted in male and female patients, 30 - 80 years of age with painful OA of the index knee with Kellgren-Lawrence (K-L) Grade 2, 3 or 4.

Part 1 - SAD Phase: Up to three ascending doses of FX201 (low dose, mid dose and high dose) will be tested in cohorts of 5-8 patients. Each patient will only receive one injection of FX201. A maximum of 24 patients will be enrolled (range 15 to 24).

When a minimum of 4 weeks have elapsed since the last patient of the current cohort has been treated, all safety data will be collected and reviewed by an independent Data Monitoring Committee (DMC). After evaluating cohort safety data, the DMC will evaluate continuing the trial and initiating treatment in the next dosing cohort as well as expanding enrollment in dose level(s).

Part 2 - Expansion Phase: After the DMC has met to review safety data from each Cohort and has recommended expanding dose level(s), enrollment slots for dose levels reviewed by the DMC will be opened. A maximum of 105 patients [up to an additional 35 patients per dose level (up to 20 FX201 alone and up to 15 FX201 with IA methylprednisolone 40 mg/mL pre-treatment)].

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 72
• Est. completion date: November 28, 2026
• Est. primary completion date: November 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• Written consent to participate in the study

• Male or female 30 to 80 years of age, inclusive, on the day of enrollment (Day 1)

• Body mass index (BMI) = 40 kilograms per meters squared (kg/m2)

• Clinical diagnosis of OA of the knee on the American College of Rheumatology criteria (Altman, 1986) with radiologic evidence of OA (K-L Grade 2 or 3 for SAD Phase Cohort A and K-L Grade 2, 3 or 4 for SAD Phase Cohorts B and C and the Expansion Phase) at the index joint at the screening visit

• Moderate pain in the index joint

• Failed two or more types of conservative therapy for index knee osteoarthritis (e.g., structured exercise programs, topical or oral non-steroidal anti-inflammatory therapies); or failed one prior type of conservative therapy and at least one prior index knee IA treatment (corticosteroid or hyaluronic acid)

• Sexually active females and males agree to use highly effective methods of contraception

Exclusion Criteria:

• Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease

• History of or current infection in the index knee joint

• Inability to undergo Magnetic Resonance Imaging (MRI) due to presence of surgical hardware or other foreign body in the index knee

• Unstable index knee joint (e.g., torn anterior cruciate ligament, etc.) within 12 months of Screening

• Any IA drug/biologic use within 6 months of Screening or 5 half-lives (whichever is longer) (e.g., IA corticosteroid, IA hyaluronic acid, platelet rich plasma injection, stem cells, prolotherapy and amniotic fluid injection, etc.)

• Cold or radiofrequency nerve ablation of the index knee within 12 months of Screening

• Arthroscopic or open surgery on the index knee within 12 months of Screening or planned/anticipated surgery on the index knee for the study period

• Anticipated major surgery during the study period

• Laboratory values that meet exclusion criteria

• ECG abnormality at Screening or Baseline judged clinically significant

• Use of immunomodulators, immunosuppressive, or chemotherapeutic agents within 5 years of Screening

• Use of any other investigational drug, biologic or device within 3 months of Screening

• Any systemic or local bacterial or viral infection requiring IV antibiotics or antivirals within 4 weeks of Screening or oral antibiotics or antivirals within 2 weeks of Screening

• Known allergy or sensitivity to methylprednisolone

• Any other clinically significant acute or chronic medical conditions (e.g., bleeding disorder) that, in the judgment of the Investigator, would preclude the use of an IA injection or that could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study

Note: Other protocol defined inclusion/exclusion criteria apply.

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Biological:
• FX201
FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.

Locations

Country	Name	City	State
United States	University Orthopedics Center	Altoona	Pennsylvania
United States	Metroplex Clinical Research Center	Dallas	Texas
United States	Physicians' Research Options/The SMART Clinic	Draper	Utah
United States	Altoona Center for Clinical Research	Duncansville	Pennsylvania
United States	Center for Pharmaceutical Research	Kansas City	Missouri
United States	Arizona Research Center	Phoenix	Arizona
United States	Gulfcoast Research Institute, LLC	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Outcome Measure: Incidence of treatment emergent adverse events after a single intra-articular (IA) injection of FX201 (safety and tolerability)	Incidence of treatment emergent adverse events after a single intra-articular (IA) injection of FX201	Baseline to Week 104
Secondary	Secondary Outcome Measure: Characterization of the systemic biodistribution of FX201 as seen through the percentage of patients positive for FX201 at Baseline, Day 1, Day 2, Week 1, Week 2, Week 3, and Week 4	The percentage of patients positive for FX201 at select timepoints	Baseline, Day 1, Day 2, Week 1, Week 2, Week 3, Week 4